3.0.0 2521 2023-01-11T13:24:46Z 2023-01-11T13:24:46Z House H HR 2013-06-26 113 From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. BEN RAY LUJAN of New Mexico:H.R. 2521.Congress has the power to enact this legislation pursuantto the following:Congress has the power to enact this legislation pursuantto the power of the Congress to regulate Commerce, asenumerated by Article I, Section 8, Clause 3 of the UnitedStates Constitution.[Page H4080]]]> hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2013-06-28T15:00:08Z Referred to 2013-06-26T14:01:00Z Cavernous Angioma Research Resource Act of 2013 113 1223 S 2013-06-26 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Identical bill CRS 2013-06-28 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2013-06-26 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2013-06-26 Introduced in House IntroReferral Intro-H 9 Library of Congress 2013-06-26 Introduced in House IntroReferral 1000 9 Library of Congress L000570 Rep. Lujan, Ben Ray [D-NM-3] Ben Lujan D NM R. 3 N L000580 Rep. Lujan Grisham, Michelle [D-NM-1] Michelle Lujan Grisham D NM 1 2013-06-26 True P000588 Rep. Pearce, Stevan [R-NM-2] Stevan Pearce R NM 2 2013-06-26 True M001142 Rep. Matheson, Jim [D-UT-4] JIM MATHESON D UT 4 2013-11-14 False F000043 Rep. Fattah, Chaka [D-PA-2] CHAKA FATTAH D PA 2 2014-06-24 False Health Drug therapy Health information and medical records Medical education Medical research Neurological disorders Research administration and funding Health 00 2013-06-26 Introduced in House 2013-09-26T22:04:06Z Cavernous Angioma Research Resource Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH), acting through the Director of the National Institute of Neurological Disorders and Stroke, to expand and intensify NIH programs regarding research and related activities concerning cavernous angioma. Authorizes grants and cooperative agreements to public or nonprofit private entities for such activities.

Authorizes the Director of NIH to: (1) conduct basic, clinical, and translational research on cavernous angioma; (2) identify and support the development of a clinical and research coordinating center with the potential of coordinating a multi-site clinical drug trial for cavernous angioma; and (3) identify and support the development of clinical and research participation centers with the potential to participate in such a trial.

Requires coordinating and participation centers to expand training programs for medical and allied health clinicians and scientists in clinical practice and research relevant to cavernous angioma.

Authorizes the Director to provide for the participation of NIH agencies in a consortium (to include at least one patient advocacy organization) to facilitate the exchange of information and increase the efficiency and effectiveness of the research effort.

Authorizes the Secretary of Health and Human Services (HHS) to award grants and cooperative agreements, including technical assistance, to public or nonprofit private entities for: (1) the collection, analysis, and reporting of data on cavernous angioma; and (2) epidemiological activities, including collecting and analyzing information on the number, incidence, correlates, and symptoms of cases and the clinical utility of specific practice patterns. Requires establishment of a national surveillance program as part of such activities.

Requires the Commissioner of Food and Drugs (FDA) to: (1) work with clinical centers, investigators, and advocates to support appropriate investigational new drug applications under the Federal Food, Drug, and Cosmetic Act in order to hasten the pace of clinical trials for cavernous angioma; and (2) where applicable in rare subpopulations of cavernous angioma requiring unique pharmacological intervention, including those with the Common Hispanic Mutation or CCM3 gene mutations, support appropriate requests for designations of orphan drugs.

]]> Cavernous Angioma Research Resource Act of 2013 Display Title Cavernous Angioma Research Resource Act of 2013 Official Title as Introduced To amend the Public Health Service Act to expand and intensify programs of the National Institutes of Health and the Centers for Disease Control and Prevention with respect to translational research and related activities concerning cavernous angioma, and for other purposes. Introduced in House IH Short Titles as Introduced Cavernous Angioma Research Resource Act of 2013 Introduced in House 2013-06-26T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-113hr2521ih/xml/BILLS-113hr2521ih.xml 2013-06-28 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.